Sugi Predict

Sugi Predict / Compounds / SCHEMBL1483138

SCHEMBL1483138

SCHEMBL1483138

O=C(O)Cn1cc(-c2ccc(Cl)cc2Cl)nc1C=Cc1ccc(-c2ccc(O)cc2)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 3/20 0.42
▸ MEN1 O00255 2/20 0.42
▸ KMT2A Q03164 2/20 0.42
▸ MAPT P10636 1/20 0.42
▸ MARS1 P56192 1/20 0.40
▸ PTGS1 P23219 2/20 0.39
▸ PTGS2 P35354 2/20 0.39
▸ KDM4E B2RXH2 2/20 0.37
▸ NPC1 O15118 1/20 0.37
▸ CRHBP P24387 1/20 0.37
▸ RAB9A P51151 1/20 0.37
▸ CRHR2 Q13324 1/20 0.37
▸ AR P10275 1/20 0.37
▸ CNR1 P21554 2/20 0.36
▸ HPGD P15428 1/20 0.36
▸ PPARG P37231 1/20 0.36
▸ NCOA2 Q15596 1/20 0.36
▸ NCOA1 Q15788 1/20 0.36
▸ NCOA3 Q9Y6Q9 1/20 0.36
▸ LMNA P02545 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1483135 1.00 SMN1; SMN2 (0.42) SMN1; SMN2MEN1KMT2AMAPTMARS1
SCHEMBL1481089 0.89 MAPT (0.40) SMN1; SMN2MEN1KMT2AMAPTPTGS1
SCHEMBL1481595 0.89 MARS1 (0.42) SMN1; SMN2MAPTMARS1PTGS2CNR1
SCHEMBL1481592 0.89 MARS1 (0.42) SMN1; SMN2MAPTMARS1PTGS2CNR1
SCHEMBL1481091 0.89 MAPT (0.40) SMN1; SMN2MEN1KMT2AMAPTPTGS1
SCHEMBL1482040 0.87 MAOB (0.40) SMN1; SMN2MAPTMARS1KDM4ENPC1
SCHEMBL1482038 0.87 MAOB (0.40) SMN1; SMN2MAPTMARS1KDM4ENPC1
SCHEMBL1480642 0.87 MEN1 (0.45) SMN1; SMN2MEN1KMT2AMAPTMARS1
SCHEMBL1480644 0.87 MEN1 (0.45) SMN1; SMN2MEN1KMT2AMAPTMARS1
SCHEMBL1481188 0.86 SMN1; SMN2 (0.47) SMN1; SMN2MEN1KMT2AMAPTMARS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110077399-A1 Substituted Azole Derivatives as Therapeutic Agents TRANSTECH PHARMA, INC. (US) 2011-03-31 — — US disclosed
EP-1594847-A2 SUBSTITUTED AZOLE DERIVATIVES AS THERAPEUTIC AGENTS Transtech Pharma, Inc. (US) 2005-11-16 — — EP disclosed
WO-2004071447-A9 SUBSTITUTED AZOLE DERIVATIVES AS THERAPEUTIC AGENTS TRANSTECH PHARMA INC (US) 2005-10-13 — — WO disclosed
US-20040192743-A1 Substituted azole derivatives as therapeutic agents TRANSTECH PHARMA, INC. 2004-09-30 — — US disclosed
WO-2004071447-A2 SUBSTITUTED AZOLE DERIVATIVES AS THERAPEUTIC AGENTS TRANSTECH PHARMA INC. (US) 2004-08-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040192743-A1 Substituted azole derivatives as therapeutic agents PTPRS, PTPRO, PTPRJ SMN1; SMN2 4575/4885MEN1 3467/4885KMT2A 1996/4885
US-20110077399-A1 Substituted Azole Derivatives as Therapeutic Agents PTPRS, PTPRO, PTPRJ SMN1; SMN2 4575/4885MEN1 3467/4885KMT2A 1996/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.